Business Standard
Friday, Jun 01, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Sun Pharma's US arm facing more trouble
BS Reporter / Mumbai Aug 21, 2009, 01:10 IST

More law firms slap class action suits against Caraco.

There is further trouble in store for Sun Pharmaceutical Industries’ US subsidiary, Caraco Pharmaceutical Laboratories, as more law firms have initiated class action suits against the company. Caraco is already facing regulatory issues in the US.

Holzer Holzer & Fistel, a US-based law firm, has announced it would file a class action lawsuit in the District Court at Michigan on behalf of investors of Caraco Pharmaceutical Laboratories.

The lawsuit alleges the company failed to disclose problems in complying with certain US Food and Drug Administration (FDA) regulations and misrepresented or failed to disclose material information relating to its efforts to obtain FDA approval for some of its drugs.

A Sun Pharma spokesperson did not comment on the proposed legal action against the US subsidiary.

A few weeks ago, law firm Izard Nobel LLP had initiated a similar lawsuit, seeking class action status against the company in the same court on behalf of the investors of Caraco.

Another law firm, Federman & Sherwood, had also filed a similar case in the same court.

Sources said such class action suits to protect investor interests were common in the US and law firms competed with each other to get support of shareholders for fighting cases against companies.

On June 25, US marshals seized drug products from the company’s three production facilities in Michigan at Detroit, Farmington Hills and Wixom.

Up to 33 different drugs were seized and FDA banned Caraco from manufacturing and selling these drugs in the US until there was assurance that the firm complied with manufacturing standards. The action was followed Caraco’s continued failure to meet FDA’s good manufacturing practices (cGMP) requirements.

Sun Pharma, which earns over 10 per cent of its Rs 4,272-crore turnover from business with Caraco, holds a 76 per cent stake in the company.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets post worst May performace since 2006
- Kavveri Telecom Q4 net declines over 6%
- Wall Street opens flat on economy worries
- RIM to set up first BlackBerry innovation zone in India
- Rajaratnam bragged about sources of inside info: Gupta lawyers
  Read Business news in 
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol.
- Watch The Film Here. Click here to know more..
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- One Partnership Endless Possibilities. Click here to know more
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- Slowdown gets worse, GDP growth sinks to 9-year low
- India to be $2-trn economy by FY13-end?
- India Inc ready to shift to other side of the dot on www
- Bharat Bandh sussessful in Chhattisgarh
- IIT alumni to move court on changes in JEE
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us